Ha ha, Seasons greetings to you, dragon slayer. I believe that...

Ha ha, Seasons greetings to you, dragon slayer. I believe that end of trial data would definitely have the most leverage. So until data, or end of trial, whichever comes first, buying while cheap is where it's at.

Thanks though, man.... My post was more about trying to find an answer to the suggestion that French couldn't land a deal, but I can't see that big pharma is clueless about the MOA, or anybody's ability to communicate the possibilities, both clinically and financially. Is there some angle that's possibly missing that COULD have potentially landed a deal prior? If not, why blame French? If after phase I/II data is what they are waiting for, then manipulation and where the stock is now is to be expected...so take advantage of its low price now, right?